TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Has Average Price Target of $2.67 According to Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been given an average recommendation of “Hold” by the eight ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $2.67.

A number of brokerages have issued reports on TCRX. Weiss Ratings lowered TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Lifesci Capital cut TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Wedbush lowered TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research note on Wednesday, September 2nd. Finally, Benchmark restated a “buy” rating on shares of TScan Therapeutics in a report on Thursday, August 13th.

TScan Therapeutics Price Performance

NASDAQ TCRX opened at $0.32 on Friday. The business has a fifty day moving average price of $0.57 and a 200 day moving average price of $0.87. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.37 and a current ratio of 3.37. The company has a market cap of $21.72 million, a P/E ratio of -0.35 and a beta of 1.15. TScan Therapeutics has a one year low of $0.29 and a one year high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. The business had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.88 million. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%. Research analysts anticipate that TScan Therapeutics will post -0.79 EPS for the current fiscal year.

Institutional Trading of TScan Therapeutics

Several hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in TScan Therapeutics by 19.6% during the 1st quarter. Renaissance Technologies LLC now owns 1,364,783 shares of the company’s stock worth $1,378,000 after purchasing an additional 223,714 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at approximately $975,000. GSA Capital Partners LLP purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at approximately $537,000. NewEdge Wealth LLC acquired a new stake in shares of TScan Therapeutics in the 2nd quarter valued at $90,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of TScan Therapeutics during the 1st quarter worth $63,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T cell receptor (TCR) engineered T cell therapies for the treatment of cancer. The company’s approach is designed to equip a patient’s T cells with tumor-specific TCRs that can recognize cancer-related targets presented on the surface of tumor cells.

TScan’s research and development programs address both solid tumors and hematologic malignancies. Its platform is intended to identify and validate cancer targets and matching TCRs, which may support the development of multiple targeted cell therapies for patients whose tumors express particular antigens.